<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376744</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-9361</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in infectious disease</Title><ISOAbbreviation>Ther Adv Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Update on invasive fungal infections: emerging trends in the incidence of fungal infections in immunosuppressed patients and associated conditions.</ArticleTitle><Pagination><StartPage>20499361241282835</StartPage><MedlinePgn>20499361241282835</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20499361241282835</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/20499361241282835</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmanton-García</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6766-8297</Identifier><AffiliationInfo><Affiliation>Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Herderstraße 52, Cologne 50931, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Infect Dis</MedlineTA><NlmUniqueID>101606715</NlmUniqueID><ISSNLinking>2049-9361</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antifungal diagnostic tools</Keyword><Keyword MajorTopicYN="N">Antifungal resistance</Keyword><Keyword MajorTopicYN="N">Antifungal therapy</Keyword><Keyword MajorTopicYN="N">Aspergillus</Keyword><Keyword MajorTopicYN="N">COVID-19-associated fungal infections</Keyword><Keyword MajorTopicYN="N">Candida</Keyword><Keyword MajorTopicYN="N">Cryptococcus spp.</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Invasive fungal infections</Keyword><Keyword MajorTopicYN="N">Mucorales</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376744</ArticleId><ArticleId IdType="pmc">PMC11457195</ArticleId><ArticleId IdType="doi">10.1177/20499361241282835</ArticleId><ArticleId IdType="pii">10.1177_20499361241282835</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rambaldi B, Russo D, Pagano L. Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice. Mediterr J Hematol Infect Dis 2017; 9: e2017012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224802</ArticleId><ArticleId IdType="pubmed">28101316</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Wu J, Wang Q, et al.. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 2023; 13: 82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10188596</ArticleId><ArticleId IdType="pubmed">37193689</ArticleId></ArticleIdList></Reference><Reference><Citation>Raje NS, Anaissie E, Kumar SK, et al.. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 2022; 9: e143–e161.</Citation><ArticleIdList><ArticleId IdType="pubmed">35114152</ArticleId></ArticleIdList></Reference><Reference><Citation>Valkovic T, Marcelic L, Valkovic F. Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases. Ther Adv Infect Dis 2024; 11: 20499361241238518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10966984</ArticleId><ArticleId IdType="pubmed">38545449</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis 2024; 24: e428–e438.</Citation><ArticleIdList><ArticleId IdType="pubmed">38224705</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes R, Sabino R, Cunha C, et al.. Multicentric study on the clinical mycology capacity and access to antifungal treatment in Portugal. Mycopathologia 2024; 189: 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10808446</ArticleId><ArticleId IdType="pubmed">38265528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs R, Majoros L, Stemler J, et al.. Unveiling the Hungarian landscape of laboratory and clinical management capacities for invasive fungal infections: navigating the frontlines against fungal menaces. Ther Adv Infect Dis 2023; 10: 20499361231219315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10729621</ArticleId><ArticleId IdType="pubmed">38116297</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantic N, Barac A, Mano V, et al.. Mapping the path to excellence: evaluation of the diagnostic and treatment tools for invasive fungal infections in the Balkans. J Infect Public Health 2024; 17: 102493.</Citation><ArticleIdList><ArticleId IdType="pubmed">38970927</ArticleId></ArticleIdList></Reference><Reference><Citation>Riera F, Caeiro JP, Cornely OA, et al.. The Argentinian landscape of mycological diagnostic capacity and treatment accessibility. Med Mycol 2023; 61: myad058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313093</ArticleId><ArticleId IdType="pubmed">37312404</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmanton-Garcia J, Au WY, Hoenigl M, et al.. The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents 2023; 61: 106718.</Citation><ArticleIdList><ArticleId IdType="pubmed">36640851</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmanton-Garcia J, Hoenigl M, Gangneux JP, et al.. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. Lancet Microbe 2023; 4: e47–e56.</Citation><ArticleIdList><ArticleId IdType="pubmed">36463916</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmanton-Garcia J, Hoenigl M, Salzer HJF, et al.. The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections. Mycoses 2023; 66: 1056–1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">37592370</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmanton-Garcia J, Simon M, Groll AH, et al.. Insights into invasive fungal infection diagnostic and treatment capacities in tertiary care centres of Germany. JAC Antimicrob Resist 2024; 6: dlae083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11135635</ArticleId><ArticleId IdType="pubmed">38812581</ArticleId></ArticleIdList></Reference><Reference><Citation>Vena A, Bassetti M, Mezzogori L, et al.. Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape. Infection 2024; 52: 197–208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10811091</ArticleId><ArticleId IdType="pubmed">37656348</ArticleId></ArticleIdList></Reference><Reference><Citation>Driemeyer C, Falci DR, Oladele RO, et al.. The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe 2022; 3: e464–e470.</Citation><ArticleIdList><ArticleId IdType="pubmed">35659908</ArticleId></ArticleIdList></Reference><Reference><Citation>Falci DR, Pasqualotto AC. Clinical mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities. Mycoses 2019; 62: 368–373.</Citation><ArticleIdList><ArticleId IdType="pubmed">30614600</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Bilal H, Shafiq M, et al.. Distribution of Aspergillus species and risk factors for aspergillosis in mainland China: a systematic review. Ther Adv Infect Dis 2024; 11: 20499361241252537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11149451</ArticleId><ArticleId IdType="pubmed">38835831</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid R, Khanum I, Habib K, et al.. Clinical characteristics, outcome, and factors associated with mortality of pulmonary mucormycosis: a retrospective single-center study from Pakistan. Ther Adv Infect Dis 2024; 11: 20499361241251744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11075588</ArticleId><ArticleId IdType="pubmed">38716078</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel) 2019; 5: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6462913</ArticleId><ArticleId IdType="pubmed">30901907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazi BK, Rackimuthu S, Wara UU, et al.. Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic. Am J Trop Med Hyg 2021; 105: 1144–1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592182</ArticleId><ArticleId IdType="pubmed">34460426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornely OA, Alastruey-Izquierdo A, Arenz D, et al.. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19: e405–e421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8559573</ArticleId><ArticleId IdType="pubmed">31699664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudramurthy SM, Hoenigl M, Meis JF, et al.. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021; 64: 1028–1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447004</ArticleId><ArticleId IdType="pubmed">34133816</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal N, Ali AS, Zahid A, et al.. Fungal empyema thoracis, a rare but an emerging entity: a retrospective case series from Pakistan. Ther Adv Infect Dis 2024; 11: 20499361231223887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10757795</ArticleId><ArticleId IdType="pubmed">38164127</ArticleId></ArticleIdList></Reference><Reference><Citation>Schauwvlieghe A, Rijnders BJA, Philips N, et al.. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6: 782–792.</Citation><ArticleIdList><ArticleId IdType="pubmed">30076119</ArticleId></ArticleIdList></Reference><Reference><Citation>Blot SI, Taccone FS, Van den Abeele AM, et al.. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186: 56–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">22517788</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmanton-Garcia J, Sprute R, Stemler J, et al.. COVID-19-associated pulmonary aspergillosis, March–August 2020. Emerg Infect Dis 2021; 27: 1077–1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007287</ArticleId><ArticleId IdType="pubmed">33539721</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler P, Bassetti M, Chakrabarti A, et al.. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21: e149–e162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833078</ArticleId><ArticleId IdType="pubmed">33333012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenigl M, Seidel D, Sprute R, et al.. COVID-19-associated fungal infections. Nat Microbiol 2022; 7: 1127–1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362108</ArticleId><ArticleId IdType="pubmed">35918423</ArticleId></ArticleIdList></Reference><Reference><Citation>Quincho-Lopez A, Poma N, Jose Montenegro-Idrogo J. COVID-19 associated with cryptococcosis: a scoping review. Ther Adv Infect Dis 2024; 11: 20499361241232851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868154</ArticleId><ArticleId IdType="pubmed">38361915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulloque-Badaracco JR, Copaja-Corzo C, Hernandez-Bustamante EA, et al.. Fungal infections in patients after recovering from COVID-19: a systematic review. Ther Adv Infect Dis 2024; 11: 20499361241242963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11070125</ArticleId><ArticleId IdType="pubmed">38706456</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacinta A, Blazquez Z, Garcia Clemente P, et al.. Aspergillus granulosus femoral osteomyelitis in a cardiac transplant patient: first reported case and literature review. Ther Adv Infect Dis 2024; 11: 20499361241231482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868480</ArticleId><ArticleId IdType="pubmed">38361916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al.. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24(Suppl. 1): e1–e38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29544767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez A, Rodriguez B, Velasquez K, et al.. Determining the usefulness of systematic (18)F-FDG PET/CT for the management of invasive fungal infection (PETIFI project): a prospective national multicentre cohort study protocol. BMJ Open 2023; 13: e074240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10314664</ArticleId><ArticleId IdType="pubmed">37355275</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clin Infect Dis 2020; 71: 685–692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384309</ArticleId><ArticleId IdType="pubmed">32170948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolat MM, Rodrigues DRR, Silveira LG, et al.. Screening with urine Histoplasma antigen test in asymptomatic patients starting TNF-alpha inhibitor therapy: a cohort study. Ther Adv Infect Dis 2024; 11: 20499361231222134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10768624</ArticleId><ArticleId IdType="pubmed">38188359</ArticleId></ArticleIdList></Reference><Reference><Citation>Falci DR, Dalla Lana DF, Pasqualotto AC. The era of histoplasmosis in Brazilian endemic mycoses. Lancet Reg Health Am 2021; 3: 100037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9903817</ArticleId><ArticleId IdType="pubmed">36777401</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin CA, Luong ML. Update on therapeutic approaches for invasive fungal infections in adults. Ther Adv Infect Dis 2024; 11: 20499361231224980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799587</ArticleId><ArticleId IdType="pubmed">38249542</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina F, Acerbis A, Oltolini C, et al.. Coadministration of isavuconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Ther Adv Infect Dis 2024; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11440545</ArticleId><ArticleId IdType="pubmed">39351448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigera LSM, Denning DW. Flucytosine and its clinical usage. Ther Adv Infect Dis 2023; 10: 20499361231161387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10084540</ArticleId><ArticleId IdType="pubmed">37051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprute R, Duda S, Liekweg A, et al.. The silent flucytosine shortage in Europe - not a distant problem. Lancet Reg Health Eur 2023; 30: 100658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10245318</ArticleId><ArticleId IdType="pubmed">37293188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>